Test Approved to Help Determine Cause of Membranous Glomerulonephritis — Physician’s First Watch
Test Approved to Help Determine Cause of Membranous Glomerulonephritis
By Kelly Young
The FDA has approved the Euroimmun Anti-PLA2R IFA blood test to determine whether a patient's membranous glomerulonephritis (MGN) is autoimmune or related to another cause, like infection. About 85% of MGNs are considered primary (i.e., autoimmune) versus secondary (i.e., related to infections or tumors).
The test detects an antibody specific to primary MGN. In a study of 560 blood samples of patients with primary MGN and other kidney disorders, the assay accurately detected primary MGN 77% of the time and gave false-positive results less than 1% of the time.
The FDA notes that the test should not be the sole method used to make a diagnosis of primary MGN. Symptoms and other laboratory tests should also be taken into account. A kidney biopsy is required for confirmation.